A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

NCT06894771 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Neoplasm

Interventions

BIOLOGICAL: MK-4700
BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC